Protalix BioTherapeutics to Engage Investors at Major Conference
Protalix BioTherapeutics, Inc. (NYSE American: PLX), a pioneering biopharmaceutical company, is gearing up for a significant event in the biopharma industry. The company has announced its participation in the 3rd Annual H.C. Wainwright BioConnect Investor Conference. This event represents a unique opportunity for Protalix to showcase its innovative work in developing recombinant therapeutic proteins.
The conference is set to take place at the Nasdaq headquarters. This event will be marked by valuable presentations and one-on-one meetings that highlight the advancements made by Protalix in the realm of biopharmaceuticals.
Details About the Investor Conference
The 3rd Annual H.C. Wainwright BioConnect Investor Conference promises to be a noteworthy gathering for investors and industry leaders alike. Protalix's Chief Financial Officer, Eyal Rubin, will take the stage to deliver a presentation that outlines the company’s strategic vision, recent developments, and future projects.
Additionally, he will be available for individual investor meetings throughout the day. This approach allows for detailed discussions and an opportunity for investors to ask questions regarding Protalix's advancements and overall business strategy.
Webcast Information
For those unable to attend in person, a webcast of the live presentation will be available at 4:30 PM EDT. This webcast will give a wider audience a chance to learn about the innovative developments Protalix is engaged in, further reinforcing its commitment to transparency and investor relations.
The webcast can be accessed through the official company website, ensuring that all interested parties have the opportunity to stay updated.
About Protalix BioTherapeutics
Protalix BioTherapeutics is at the forefront of biopharmaceutical innovation, primarily focusing on the development and commercialization of therapeutic proteins that are expressed through its proprietary plant cell-based expression system known as ProCellEx. This groundbreaking technology represents a significant advancement in the way biological drugs can be produced on a large scale.
Notably, Protalix has achieved a remarkable milestone by becoming the first company to receive FDA approval for a product developed using a plant cell-based suspension expression system. This framework not only opens new avenues for drug development but also positions Protalix as a leader in the biopharmaceutical sector.
Current Products and Collaborations
The company's pipeline includes several proprietary therapeutic proteins designed to address significant medical needs. Protalix has entered into a partnership with Pfizer Inc., granting the latter global rights for the development and commercialization of taliglucerase alfa, a treatment for Gaucher disease.
In addition to taliglucerase alfa, Protalix's second product, Elfabrio, has gained important regulatory approvals, including from the FDA and the European Medicines Agency. The global commercialization of Elfabrio is now being managed in partnership with Chiesi Farmaceutici S.p.A., further showcasing Protalix's commitment to collaboration in achieving widespread patient access to their therapies.
Commitment to Innovation
Protalix’s development pipeline features a variety of product candidates aimed at addressing well-established pharmaceutical markets. These include PRX–115, a PEGylated uricase intended for treating uncontrolled gout, and PRX–119, which targets NETs-related diseases. This broad spectrum of focus illustrates Protalix's dedication to meeting diverse healthcare needs through innovation.
Frequently Asked Questions
What is the purpose of the H.C. Wainwright BioConnect Investor Conference?
The conference serves as a platform for biopharmaceutical companies to present their advancements to potential investors and facilitate direct communication with industry stakeholders.
Who is representing Protalix at the conference?
Eyal Rubin, the Chief Financial Officer of Protalix, will be delivering a presentation and engaging with investors during the event.
How can interested investors follow the conference?
Investors can access a live webcast of Protalix's presentation on the company’s website, providing an opportunity to stay informed about the company’s updates.
What unique technology does Protalix use for drug development?
Protalix utilizes the ProCellEx system, a proprietary plant cell-based expression method that allows for the efficient production of therapeutic proteins.
What are some of Protalix's current products?
Protalix's current products include taliglucerase alfa for Gaucher disease and Elfabrio, which was approved recently for various treatments.
